Affordable Access

deepdyve-link
Publisher Website

The morbidity of C. difficile in necrotizing pancreatitis.

Authors
  • Maatman, Thomas K1
  • Westfall-Snyder, Jamaica A2
  • Nicolas, Megan E1
  • Yee, Elliott J2
  • Ceppa, Eugene P1
  • House, Michael G1
  • Nakeeb, Attila1
  • Schmidt, C Max1
  • Zyromski, Nicholas J3
  • 1 Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA. , (India)
  • 2 Indiana University School of Medicine, Indianapolis, IN, USA. , (India)
  • 3 Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: [email protected] , (India)
Type
Published Article
Journal
American journal of surgery
Publication Date
Mar 01, 2020
Volume
219
Issue
3
Pages
509–512
Identifiers
DOI: 10.1016/j.amjsurg.2019.08.006
PMID: 31427035
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Necrotizing pancreatitis (NP) patients commonly require antibiotic treatment during the several month-long disease course. We hypothesized that Clostridium difficile infection (CDI) is common in NP and significantly impacts outcomes. Retrospective review of 704 NP patients treated at a single-institution (2005-2018). 10% (67/704) of patients developed CDI a mean 78 days after NP onset. Patients developing CDI experienced increased total hospital days (CDI, 104; No CDI, 42; P < 0.001), readmission rates (CDI, 85%; No CDI, 64%; P = 0.006), and duration of NP (CDI, 248 days; No CDI, 183; P = 0.001). Risk factors for CDI included antibiotic use (OR, 96.2; 95% CI, 5.9-1556.2; P = 0.001) and any organ failure (OR, 2.0; 95% CI, 1.2-3.3, P = 0.008). Mortality was not affected by CDI (CDI, 10%; No CDI, 9%; P = 0.7). Clostridium difficile infection is common in necrotizing pancreatitis and negatively impacts morbidity and disease recovery. Copyright © 2019 Elsevier Inc. All rights reserved.

Report this publication

Statistics

Seen <100 times